Marker Therapeutics Q1 EPS $(0.27) Up From $(0.57) YoY, Sales $1.24M Up From $1.23M YoY
Marker Therapeutics Q1 EPS $(0.27) Up From $(0.57) YoY, Sales $1.24M Up From $1.23M YoY
Marker Therapeutics第一季度每股收益爲0.27美元，高於同比0.57美元，銷售額爲124萬美元，同比增長123萬美元
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.27) per share. This is a 52.63 percent increase over losses of $(0.57) per share from the same period last year. The company reported $1.24 million in sales this quarter. This is a 0.79 percent increase over sales of $1.23 million the same period last year.
Marker Therapeutics（納斯達克股票代碼：MRKR）報告稱，季度每股虧損爲0.27美元。與去年同期每股虧損0.57美元（0.57）相比，增長了52.63％。該公司報告本季度銷售額爲124萬美元。這比去年同期的123萬美元銷售額增長了0.79％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。